Genzyme Wins fight for AnorMED | Chemical & Engineering News
Volume 84 Issue 43 | p. 29
Issue Date: October 23, 2006

Genzyme Wins fight for AnorMED

Department: Business

Ending a takeover fight, Genzyme will acquire AnorMED for $13.50 per share, or about $580 million. Genzyme bid $355 million for AnorMED at the end of August but was rejected by the Canadian biotech firm. Millennium Pharmaceuticals later stepped in with an offer of $515 million. After Genzyme revised its offer, Millennium withdrew from bidding. Both firms are interested in AnorMED's Mozobil, a hematology-oncology therapy now in Phase III clinical trials.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment